Oral-Absorption-Enhancing Drug-Delivery Technology - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Oral-Absorption-Enhancing Drug-Delivery Technology
The authors examine an oral-absorption-enhancement technology based on surface-active materials to increase apical membrane fluidity in vitro.

Pharmaceutical Technology
Volume 35, pp. s12-s14


The GIPET technology is an advanced-stage permeation enhancement oral drug-delivery platform based on enhancers that have been studied in cells, tissues, rodents, dogs, and humans to demonstrate their ability to promote drug absorption, safety, reversibility, and mechanism of action. The technology is suitable for a wide range of different molecule types as evidenced by the preclinical and clinical studies showing enhanced intestinal absorption.


The authors thank David Brayden, professor at the University College Dublin in Ireland for critical reading of the manuscript. The authors also want to acknowledge that the work of Edwin Walsh is funded by an Irish Research Council for Science, Engineering and Technology (IRCSET)–Industry Partnership between the Irish Government and Merrion Pharmaceuticals.

Edwin G. Walsh, BSc, is a PhD student at the School of Veterinary Medicine and Conway Institute, University College Dublin, in Dublin, Ireland. Alan P. Cullen, MSc, is preclinical development manager, John S. Fox, PhD, MBA, is chief development officer, and Thomas W. Leonard*, RPh, PhD, is vice-president and chief scientific officer, all at Merrion Pharmaceuticals, 219 Racine Drive, Suite D, Wilmington, NC 28403, tel. 910.799.1847, fax 910.395,1843,


1. E. Windsor and G.E. Cronheim, Nature 190 (4772), 263–264 (1961).

2. M. Hayashi, M. Tomita, and A. Awazu, Adv. Drug Deliv. Rev. 28 (2), 191–204 (1997).

3. T. Lindmark, T. Nikkila, and P. Artursson, J. Pharmacol. Exp. Ther. 275 (2), 958–964 (1995).

4. H. Huang and R.E. Verall, J. Solution Chem. 26 (2) 135–162 (1997).

5. Y. Lo and J. Huanh, Biochem. Pharmacol. 59 (6), 665–672 (2000).

6. JECFA, 29th Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series No. 733 (1986).

7. L. Blomquist, Gastroenterol. 32 (8), 805–812 (1997).

8. A.J. Ryan, R-T. Chang, and C.V. Gisolfi, Med. & Sci. in Sports & Exerc. 28 (6), 698–705 (1996).

9. T.T. Kararli, Biopharm. Drug Dispos. 16 (5), 351–380 (1995).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here